Fortrea Holdings Inc.

Valuation Analysis

About the Company

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. T

Fortrea Holdings Inc. Stock at a Glance

Fortrea Holdings Inc. (FTRE) is currently trading at $16.48 with a market capitalization of $1.6B. The 52-week range spans from $4.36 to $18.67; the current price is 11.7% below the yearly high. Year-over-year revenue growth stands at -2.3%.

💰 Dividend

Fortrea Holdings Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

11 analysts rate Fortrea Holdings Inc. (FTRE) on consensus: Buy. The average price target is $16.21, implying -1.64% from the current price. Analyst price targets range from $9.50 to $20.00.

Fortrea Holdings Inc.: The Investment Case in Detail

Fortrea Holdings Inc. (FTRE) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Revenue is contracting at -2.3% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 212.7% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valuation in Context

With a PEG ratio of 0.34, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity. The EV/EBITDA multiple of 36.2x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to above-average price swings, elevated short interest (11.79%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Fortrea Holdings Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.